AIMS: To assess the effect of the calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response to sublingual nitroglycerin (NTG). METHODS:Twenty-two healthy male volunteers participated in a randomized, placebo-controlled, double-blind, two-period, crossover study. Subjects received 500 mg telcagepant or placebo followed, 1.5 h later, by 0.4 mg NTG. To assess the haemodynamic response the following vascular parameters were measured: blood pressure, aortic augmentation index (AIx) and brachial artery diameter (BAD). Data are presented as mean (95% confidence interval, CI). RESULTS: The aortic AIx following NTG decreased by -18.50 (-21.02, -15.98) % after telcagepant vs. -17.28 (-19.80, -14.76) % after placebo. The BAD fold increase following NTG was 1.14 (1.12, 1.17) after telcagepant vs. 1.13 (1.10, 1.15) after placebo. For both AIx and BAD, the hypothesis that telcagepant does not significantly affect the changes induced by NTG is supported (P < 0.0001). In addition, no vasoconstrictor effect of telcagepant could be demonstrated. CONCLUSIONS:Telcagepant did not affect NTG-induced haemodynamic changes. These data suggest that NTG-induced vasodilation is not CGRP dependent.
RCT Entities:
AIMS: To assess the effect of the calcitonin gene-related peptide (CGRP) receptor antagonist, telcagepant, on the haemodynamic response to sublingual nitroglycerin (NTG). METHODS: Twenty-two healthy male volunteers participated in a randomized, placebo-controlled, double-blind, two-period, crossover study. Subjects received 500 mg telcagepant or placebo followed, 1.5 h later, by 0.4 mg NTG. To assess the haemodynamic response the following vascular parameters were measured: blood pressure, aortic augmentation index (AIx) and brachial artery diameter (BAD). Data are presented as mean (95% confidence interval, CI). RESULTS: The aortic AIx following NTG decreased by -18.50 (-21.02, -15.98) % after telcagepant vs. -17.28 (-19.80, -14.76) % after placebo. The BAD fold increase following NTG was 1.14 (1.12, 1.17) after telcagepant vs. 1.13 (1.10, 1.15) after placebo. For both AIx and BAD, the hypothesis that telcagepant does not significantly affect the changes induced by NTG is supported (P < 0.0001). In addition, no vasoconstrictor effect of telcagepant could be demonstrated. CONCLUSIONS: Telcagepant did not affect NTG-induced haemodynamic changes. These data suggest that NTG-induced vasodilation is not CGRP dependent.
Authors: B J Van der Schueren; A Rogiers; F H Vanmolkot; A Van Hecken; M Depré; S A Kane; I De Lepeleire; S R Sinclair; J N de Hoon Journal: J Pharmacol Exp Ther Date: 2008-01-23 Impact factor: 4.030
Authors: Christopher A Salvatore; James C Hershey; Halea A Corcoran; John F Fay; Victor K Johnston; Eric L Moore; Scott D Mosser; Christopher S Burgey; Daniel V Paone; Anthony W Shaw; Samuel L Graham; Joseph P Vacca; Theresa M Williams; Kenneth S Koblan; Stefanie A Kane Journal: J Pharmacol Exp Ther Date: 2007-11-26 Impact factor: 4.030
Authors: Tony W Ho; Michel D Ferrari; David W Dodick; Vince Galet; James Kost; Xiaoyin Fan; Heather Leibensperger; Samar Froman; Christopher Assaid; Christopher Lines; Hille Koppen; Paul K Winner Journal: Lancet Date: 2008-11-25 Impact factor: 79.321
Authors: David Monteith; Emily C Collins; Corinne Vandermeulen; Anne Van Hecken; Eyas Raddad; Joel C Scherer; David Grayzel; Thomas J Schuetz; Jan de Hoon Journal: Front Pharmacol Date: 2017-10-17 Impact factor: 5.810
Authors: Jan de Hoon; Anne Van Hecken; Corinne Vandermeulen; Marissa Herbots; Yumi Kubo; Ed Lee; Osa Eisele; Gabriel Vargas; Kristin Gabriel Journal: Cephalalgia Date: 2018-05-21 Impact factor: 6.292